Dapagliflozin, an SGLT2 inhibitor, for diabetes
Authors:
- Markolf HanefeldMHMarkolf Hanefeld
- Thomas ForstTFThomas Forst
- 1 June 2010
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 375 (9733) , 2196-2198
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Sodium-Glucose Co-Transport InhibitorsDrugs, 2010
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialThe Lancet, 2009
- Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drugDiabetes, Obesity and Metabolism, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Urologic Complications of DiabetesDiabetes Care, 2005
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Molecular Analysis of the SGLT2 Gene in Patients with Renal GlucosuriaJournal of the American Society of Nephrology, 2003
- Cytokine secretion is impaired in women with diabetes mellitusEuropean Journal of Clinical Investigation, 2000